BUZZ - ArriVent shares fall as its lung cancer drug fails to meet goals in late-stage clinical trial
路透社2026/10/06 12:49On October 6, shares of drug developer ArriVent BioPharma (AVBP.O) dropped 62.7% to $10.62 in pre-market trading. The company stated that its experimental drug firmonertinib failed to significantly delay disease progression or death in a late-stage clinical trial involving 398 previously untreated patients with advanced lung cancer associated with a rare genetic mutation. In the higher-dose group, the median time patients lived without cancer progression was 11 months, compared to 9.5 months in the chemotherapy group; additionally, 60% of patients saw tumor shrinkage, versus 33% in the chemotherapy group. In the high-dose group, 52% of patients experienced serious side effects, compared to 55% in the chemotherapy group; no new safety issues were reported. ArriVent is reviewing the full results to determine the next steps for the drug's development. As of the previous trading day's close, AVBP had risen 41.5% so far this year. (For ease of use by non-English speakers, Reuters offers its reports translated automatically into several languages. Automated translations may be inaccurate or may not adequately convey the intended meaning. Reuters does not guarantee the accuracy of these translations and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses incurred from the use of the automated translation service.)
October 6 - ** Drug developer ArriVent BioPharma (AVBP.O) shares fell 62.7% to $10.62 in pre-market trading
** The company stated that its experimental drug firmonertinib (link) failed to significantly delay disease progression or death in a late-stage clinical trial involving 398 previously untreated patients with advanced lung cancer associated with a rare genetic mutation
** In the higher-dose group, the median time without cancer progression was 11 months, compared to 9.5 months in the chemotherapy group; meanwhile, 60% of patients saw tumor shrinkage, versus 33% in the chemotherapy group
** In the high-dose group, 52% of patients experienced serious side effects, compared to 55% in the chemotherapy group; no new safety issues were reported
** ArriVent is reviewing the full results to decide the next steps in the drug's development
** As of the previous trading day’s close, AVBP was up 41.5% year to date
(To assist non-English native speakers, Reuters provides automated translations of its reports in several languages. Due to potential inaccuracies or missing contextual nuance in automated translations, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters accepts no liability for any damages or losses arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ondo Finance brings pre-IPO AI exposure on-chain — But there’s a catch
Philippines: One more BSP hike expected in October - Standard Chartered
The Reality of AI Agentic Payments in 2026
Federal Reserve plans major reform of bank regulatory mechanisms; Vice Chair Bowman: restructure regional framework and adjust asset thresholds
Federal Reserve Vice Chair for Supervision Bowman stated that there are plans to comprehensively reform the way all U.S. banks are regulated, by consolidating the current regulatory functions of the 12 Federal Reserve district banks into five new geographic regions. Each region will have a dedicated "regional head," aiming to change the previous situation where responsibilities and powers were decentralized. The Federal Reserve will review updates later this year regarding the asset thresholds at which banks face stricter regulatory rules, potentially providing greater room for banks to expand.
Crypto prices
More
